Intervention

Paliperidone Palmitate

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting0

Common conditions3

Lead sponsors shown7

Clinical trials

9 shown

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia PatientsNCT04572685 · 2020-01-22

The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence RiskNCT04064476 · 2019-08-18

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting InjectionNCT03390712 · 2018-01-02

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaNCT03345979 · 2017-11-15

A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With SchizophreniaNCT01947803 · 2013-09-01

A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral AntipsychoticsNCT01685931 · 2012-11-01

Paliperidone Palmitate Flexible Dosing in SchizophreniaNCT01281527 · 2010-11-01

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.NCT00111189 · 2005-02-01

Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With SchizophreniaNCT00073320 · 2003-08-01

Common conditions

Schizophrenia7 Schizophrenia Patients1 Schizophrenia Spectrum and Other Psychotic Disorders1

Leading sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.2 Xian-Janssen Pharmaceutical Ltd.2 Alkermes, Inc.1 Huazhong University of Science and Technology1 Janssen-Cilag International NV1 Luye Pharma Group Ltd.1 Réseau de Santé Vitalité Health Network1

Trial status mix

COMPLETED7

UNKNOWN2

Phase mix

PHASE34

PHASE42

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.